Sumitomo Dainippon Pharma Co Ltd (4506.T)
24 Jun 2019
Get access to over 18 million research reports from over 1,700 sources.
For several years, Reuters.com has provided analyst research reports for downloading. In an effort to streamline our website, analyst research will now be available from our dedicated page for Thomson Reuters On Demand, and the Reuters service will discontinue as of September 30, 2016.
Thomson Reuters On Demand provides over 18 million research reports from 1,700 sources.
Moreover, Thomson Reuters On Demand offers fast and cost-effective solutions that would allow you to retrieve information on:
- private equity
- third-party document and information retrieval
- and much, much more…
Click here to request a report and the team of expert analysts will get back to you shortly, to ensure you get the report you need.
|73||2018||Chairman of the Board, Representative Director|
|60||2018||President, Representative Director|
|61||2018||Managing Executive Officer, Chief Director of Sales, Head of Japan Business Unit, Director|
|2017||Managing Executive Officer, Chief Director of Production, Deputy Head of Japan Business Unit|
|2017||Managing Executive Officer, Global Head of Oncology|
- Nikkei ends flat despite strong chip makers
- Nikkei falls as financials drag; Eisai indicated to dive
- Nikkei rebounds as Fed's shift calms nerves; gains 3.8 pct in January
- Nikkei rebounds to 1-1/2-week highs as Fed's shift calms nerves
- SanBio's crash causes margin calls, drags down Japan's start-up market